Home » Business News » 2012 » October » October 1, 2012

PropThink: Sickle Cell Drug Finding New Opportunity at ADVENTRX Pharmaceuticals

October 1, 2012 -

With Orphan Drug status and a largely-unmet medical need for its primary indication, ADVENTRX Pharmaceuticals (AMEX:ANX) expects its lead candidate, ANX-188, to be the company's most important asset in the next few years. CEO Brian Culley believes the development-stage drug has the potential to reach a large segment of the Sickle Cell population in the U.S., driven by improved clinical development and proprietary manufacturing methods.
In an exclusive interview with PropThink, Culley discusses the mechanism of action for this novel drug, which had been in development for a number of years before ADVENTRX acquired it, but never moved beyond clinical trials. Culley says that the drug hasn't yet demonstrated its full capabilities, and an upcoming Phase III trial at ADVENTRX, expected to initiate by year's-end, will improve on older testing strategies. Discussing the development history of ANX-188, he says, ""It was very interesting to us to see that in a study that was underpowered and really not optimally designed, they still very nearly reached the threshold of success which is needed for FDA approval."" With better financial backing and advanced manufacturing methods, Culley believes ANX-188 will move to the market with a strong IP portfolio to protect it. The only FDA approved drug for treating Sickle Cell Anemia, hydroxyurea, is sold by Bristol-Myers Squibb (NYSE:BMY) as Hydrea and Droxia. 
The video touches on the company's other pipeline products and ADVENTRX's financial position. Culley also discusses expanding indications for ANX-188, and explains how recent hires at the company bring valuable clinical and regulatory expertise to this development-stage biotech.
Click Here to Watch this PropThink Exclusive Interview with ADVENTRX Pharmaceuticals
About PropThink
PropThink is an intelligence service that delivers long and short trading ideas to investors in the healthcare and life sciences sectors. Our focus is on identifying and analyzing technically-complicated companies and equities that are grossly over or under-valued. We offer daily market coverage, weekly feature stories, and a newsletter to investors who subscribe on To learn more, follow us on Twitter or visit us at

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: PropThink via Thomson Reuters ONE


Copyright 2012 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

ACN Newswire

Comment on this story